(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Rana McKay ...

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...

We know from the phase 2 TROPHY-U-01 trial that sacituzumab govitecan is an active drug, with an objective response rate of ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to a kidney and bladder cancers oral abstract session. Dr. Tian Zhang discussed the ...

ASCO annual meeting featured a urothelial carcinoma oral abstract session and a discussant presentation by Dr. John Sfakianos ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to a State ...

The PSA progression free survival in Arm A was 2.6 months versus 2.5 months in Arm B, and radiologic progression free survival was 2.1 months and 1.9 months in arm A and B, respectively. The median ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Matthew Siskin discussing real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) ...

ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Geoffrey Johnson discussing SECuRE, a dose escalation/expansion study to assess the anti-tumor ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Kevin Zarrabi discussing the molecular characterization of STEAP1 and STEAP2 in advanced prostate cancer. STEAP 1 and 2 ...

Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and Bladder. Dr. Brendan Raizenne presented Poster 4578: Prognostic utility ...

AURKA inhibitors might enhance outcomes of metastatic prostate cancer treated with androgen receptor pathway inhibitors by intensifying androgen receptor inhibition, increasing DNA-damage-related cell ...